Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

Nov. 7, 2000

KS Biomedix and York Medical sign high-affinity antibody deal

Nov. 7, 2000

KRN-7000 as an adjunct to surgical removal of tumors

Nov. 3, 2000

Xoma initiates phase I trial with ING-1 monoclonal antibody

Nov. 2, 2000

Melacine as adjuvant therapy in melanoma: phase III data reported at SBT meeting

Oct. 30, 2000

Immunotherapy with beta-alethine useful in minimal residual disease

Oct. 30, 2000

Therion and Aventis expand cancer vaccine alliance

Oct. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...